Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer

Masaaki Yamamoto, Tsuyoshi Takahashi, Satoshi Serada, Takahito Sugase, Koji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Shuji Takiguchi, Testsuji Naka, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Gastric cancer is one of the most common malignant tumors. Although improvement in chemotherapy has been achieved, the clinical prognosis of advanced gastric cancer remains poor. Therefore, it is increasingly important to predict the prognosis and determine whether patients should or should not receive neoadjuvant or adjuvant chemotherapy. Leucine-rich α2-glycoprotein-1 (LRG1) is overexpressed during inflammation and is associated with various malignancies. In this study, we assessed LRG1 expression in cancer specimens and in the sera of patients with cancer to clarify the usefulness of LRG1 as a biomarker in gastric cancer. This study enrolled 239 (for immunohistochemical staining; IHC) and 184 (for ELISA) patients with gastric cancer. Results of IHC showed that LRG1 expression was significantly associated with histological type, lymphatic and venous invasion, tumor and node factors, and disease stage. Overall survival was significantly worse in the high LRG1 expression group than in the low LRG1 group (P = 0.0003). Cox multivariate analysis of overall survival revealed that LRG1 expression was an independent prognostic factor (P = 0.0258). Serum LRG1 was significantly higher in gastric cancer patients than in healthy volunteers, and increased as the pathological stage progressed. Furthermore, a significant correlation was revealed between serum LRG1 level and LRG1 expression with IHC (P < 0.0001). Inhibition of LRG1 significantly decreased cell proliferation in vitro (migratory and invasive capacity of gastric cancer cells). These results suggest that LRG1 expression in tumors and serum may be a useful prognostic marker in gastric cancer patients.

Original languageEnglish
Pages (from-to)2052-2060
Number of pages9
JournalCancer Science
Volume108
Issue number10
DOIs
Publication statusPublished - Oct 2017

Fingerprint

Tumor Biomarkers
Leucine
Stomach Neoplasms
Glycoproteins
Neoplasms
Serum
Survival
Adjuvant Chemotherapy
Healthy Volunteers
Multivariate Analysis
Biomarkers
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Staining and Labeling
Inflammation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yamamoto, M., Takahashi, T., Serada, S., Sugase, T., Tanaka, K., Miyazaki, Y., ... Doki, Y. (2017). Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer. Cancer Science, 108(10), 2052-2060. https://doi.org/10.1111/cas.13329

Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer. / Yamamoto, Masaaki; Takahashi, Tsuyoshi; Serada, Satoshi; Sugase, Takahito; Tanaka, Koji; Miyazaki, Yasuhiro; Makino, Tomoki; Kurokawa, Yukinori; Yamasaki, Makoto; Nakajima, Kiyokazu; Takiguchi, Shuji; Naka, Testsuji; Mori, Masaki; Doki, Yuichiro.

In: Cancer Science, Vol. 108, No. 10, 10.2017, p. 2052-2060.

Research output: Contribution to journalArticle

Yamamoto, M, Takahashi, T, Serada, S, Sugase, T, Tanaka, K, Miyazaki, Y, Makino, T, Kurokawa, Y, Yamasaki, M, Nakajima, K, Takiguchi, S, Naka, T, Mori, M & Doki, Y 2017, 'Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer', Cancer Science, vol. 108, no. 10, pp. 2052-2060. https://doi.org/10.1111/cas.13329
Yamamoto, Masaaki ; Takahashi, Tsuyoshi ; Serada, Satoshi ; Sugase, Takahito ; Tanaka, Koji ; Miyazaki, Yasuhiro ; Makino, Tomoki ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Takiguchi, Shuji ; Naka, Testsuji ; Mori, Masaki ; Doki, Yuichiro. / Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer. In: Cancer Science. 2017 ; Vol. 108, No. 10. pp. 2052-2060.
@article{473c87cfda1c4ce69859c1e88613a7de,
title = "Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer",
abstract = "Gastric cancer is one of the most common malignant tumors. Although improvement in chemotherapy has been achieved, the clinical prognosis of advanced gastric cancer remains poor. Therefore, it is increasingly important to predict the prognosis and determine whether patients should or should not receive neoadjuvant or adjuvant chemotherapy. Leucine-rich α2-glycoprotein-1 (LRG1) is overexpressed during inflammation and is associated with various malignancies. In this study, we assessed LRG1 expression in cancer specimens and in the sera of patients with cancer to clarify the usefulness of LRG1 as a biomarker in gastric cancer. This study enrolled 239 (for immunohistochemical staining; IHC) and 184 (for ELISA) patients with gastric cancer. Results of IHC showed that LRG1 expression was significantly associated with histological type, lymphatic and venous invasion, tumor and node factors, and disease stage. Overall survival was significantly worse in the high LRG1 expression group than in the low LRG1 group (P = 0.0003). Cox multivariate analysis of overall survival revealed that LRG1 expression was an independent prognostic factor (P = 0.0258). Serum LRG1 was significantly higher in gastric cancer patients than in healthy volunteers, and increased as the pathological stage progressed. Furthermore, a significant correlation was revealed between serum LRG1 level and LRG1 expression with IHC (P < 0.0001). Inhibition of LRG1 significantly decreased cell proliferation in vitro (migratory and invasive capacity of gastric cancer cells). These results suggest that LRG1 expression in tumors and serum may be a useful prognostic marker in gastric cancer patients.",
author = "Masaaki Yamamoto and Tsuyoshi Takahashi and Satoshi Serada and Takahito Sugase and Koji Tanaka and Yasuhiro Miyazaki and Tomoki Makino and Yukinori Kurokawa and Makoto Yamasaki and Kiyokazu Nakajima and Shuji Takiguchi and Testsuji Naka and Masaki Mori and Yuichiro Doki",
year = "2017",
month = "10",
doi = "10.1111/cas.13329",
language = "English",
volume = "108",
pages = "2052--2060",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer

AU - Yamamoto, Masaaki

AU - Takahashi, Tsuyoshi

AU - Serada, Satoshi

AU - Sugase, Takahito

AU - Tanaka, Koji

AU - Miyazaki, Yasuhiro

AU - Makino, Tomoki

AU - Kurokawa, Yukinori

AU - Yamasaki, Makoto

AU - Nakajima, Kiyokazu

AU - Takiguchi, Shuji

AU - Naka, Testsuji

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2017/10

Y1 - 2017/10

N2 - Gastric cancer is one of the most common malignant tumors. Although improvement in chemotherapy has been achieved, the clinical prognosis of advanced gastric cancer remains poor. Therefore, it is increasingly important to predict the prognosis and determine whether patients should or should not receive neoadjuvant or adjuvant chemotherapy. Leucine-rich α2-glycoprotein-1 (LRG1) is overexpressed during inflammation and is associated with various malignancies. In this study, we assessed LRG1 expression in cancer specimens and in the sera of patients with cancer to clarify the usefulness of LRG1 as a biomarker in gastric cancer. This study enrolled 239 (for immunohistochemical staining; IHC) and 184 (for ELISA) patients with gastric cancer. Results of IHC showed that LRG1 expression was significantly associated with histological type, lymphatic and venous invasion, tumor and node factors, and disease stage. Overall survival was significantly worse in the high LRG1 expression group than in the low LRG1 group (P = 0.0003). Cox multivariate analysis of overall survival revealed that LRG1 expression was an independent prognostic factor (P = 0.0258). Serum LRG1 was significantly higher in gastric cancer patients than in healthy volunteers, and increased as the pathological stage progressed. Furthermore, a significant correlation was revealed between serum LRG1 level and LRG1 expression with IHC (P < 0.0001). Inhibition of LRG1 significantly decreased cell proliferation in vitro (migratory and invasive capacity of gastric cancer cells). These results suggest that LRG1 expression in tumors and serum may be a useful prognostic marker in gastric cancer patients.

AB - Gastric cancer is one of the most common malignant tumors. Although improvement in chemotherapy has been achieved, the clinical prognosis of advanced gastric cancer remains poor. Therefore, it is increasingly important to predict the prognosis and determine whether patients should or should not receive neoadjuvant or adjuvant chemotherapy. Leucine-rich α2-glycoprotein-1 (LRG1) is overexpressed during inflammation and is associated with various malignancies. In this study, we assessed LRG1 expression in cancer specimens and in the sera of patients with cancer to clarify the usefulness of LRG1 as a biomarker in gastric cancer. This study enrolled 239 (for immunohistochemical staining; IHC) and 184 (for ELISA) patients with gastric cancer. Results of IHC showed that LRG1 expression was significantly associated with histological type, lymphatic and venous invasion, tumor and node factors, and disease stage. Overall survival was significantly worse in the high LRG1 expression group than in the low LRG1 group (P = 0.0003). Cox multivariate analysis of overall survival revealed that LRG1 expression was an independent prognostic factor (P = 0.0258). Serum LRG1 was significantly higher in gastric cancer patients than in healthy volunteers, and increased as the pathological stage progressed. Furthermore, a significant correlation was revealed between serum LRG1 level and LRG1 expression with IHC (P < 0.0001). Inhibition of LRG1 significantly decreased cell proliferation in vitro (migratory and invasive capacity of gastric cancer cells). These results suggest that LRG1 expression in tumors and serum may be a useful prognostic marker in gastric cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85030167933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030167933&partnerID=8YFLogxK

U2 - 10.1111/cas.13329

DO - 10.1111/cas.13329

M3 - Article

C2 - 28746773

AN - SCOPUS:85030167933

VL - 108

SP - 2052

EP - 2060

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 10

ER -